Successes and limitations of targeted cancer therapy in melanoma.

Détails

ID Serval
serval:BIB_FC9F2F1C6482
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Successes and limitations of targeted cancer therapy in melanoma.
Périodique
Progress in Tumor Research
Auteur(s)
Romano E., Michielin O.
ISSN
2296-1887 (Electronic)
Statut éditorial
Publié
Date de publication
2014
Peer-reviewed
Oui
Volume
41
Pages
78-88
Langue
anglais
Notes
Publication types: Journal Article Publication Status: ppublish
Résumé
The treatment of stage IV melanoma has witnessed a very impressive pace of innovation in recent years, to a point where the management of these patients has very little in common to what was standard practice 5 years ago. If the gain in overall survival, the high response rates or the induction of a significant fraction of long survivors are all very exciting news for our patients and their families, the path that led to these discoveries is as important. Rather than empirical, the development of these new strategies has been extremely rational, based on state-of-the-art basic biology and immunology, exemplary translational research and, finally, hypothesis-driven targeted trials that led to rapid approval. In this review, we will cover all the new targeted therapies that have emerged as the results of these translational programs, focusing mainly on signaling pathway- and immune checkpoint-targeted therapies. Taken collectively, these new developments set the bar for a new paradigm in future translational and clinical research in both melanoma as well as other tumor types.
Pubmed
Web of science
Création de la notice
10/09/2014 9:40
Dernière modification de la notice
20/08/2019 17:27
Données d'usage